Chronic granulomatous disease (CGD) is an inherited immunodeficiency disorder affecting the microbicidal function of the phagocytes. It is characterized by susceptibility to recurrent infections leading to significant morbidity and mortality. Antibacterial and antifungal prophylaxis, though, has significantly reduced the rate and severity of the infections; the breakthrough infections still remain a challenge. Currently, allogenic haematopoietic stem cell transplantation is the only curative option which is very expensive and unavailable for many due to lack of suitable donor. Thus, prenatal diagnosis (PND) forms an important component of management in the affected families. PND is challenging in families approaching late in pregnancy with an uncharacterized molecular defect. In such cases, PND can be performed by analysis of NADPH activity of fetal blood (FB) neutrophils at 18-20 weeks of gestation. Cord blood samples at 18 weeks of gestation from healthy control were used to establish normal ranges for NBT and DHR. PND was offered for six pregnancies (NBT: n = 3, DHR: n = 6) with index cases of CGD confirmed by abnormal NBT and DHR analysis. NBT and DHR tests were found to be negative for all the six cases, confirming the same on samples post-delivery. NBT and DHR tests offer a rapid and sensitive PND of CGD in the absence of facilities for molecular diagnosis. It was observed that addition of CD15 along with CD45 led to an accurate DHR analysis. It is recommended to perform the diagnosis with adequate precautions only at centres with considerable experience and expertise in the diagnosis of CGD.
Introduction
Chronic granulomatous disease (CGD) is an inherited primary immunodeficiency disorder affecting the microbicidal function of the phagocytes, clinically characterized by recurrent infections and granulomatous lesions of the lung, liver, gastrointestinal tract, skin, lymph nodes and bones. The basic pathology of the disease is a defect in the subunits of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, which is essential for the elimination of phagocytosed organism by the respiratory burst activity. Ineffectiveness of the process of respiratory burst by the neutrophils can lead to recurrent severe bacterial and fungal infections [1] .
Mutations within any of the five known NADPH oxidase components can lead to CGD. X-linked CGD (XL-CGD) is caused by the defect in CYBB gene located on the X chromosome p21.1 encoding gp91phox.
Autosomal recessive CGD (AR-CGD) is caused by the defects in the genes NCF1, CYBA, NCF2 and NCF4 encoding for p47 phox , p22 phox , p67 phox and p40 phox , respectively [2] . The worldwide reported incidence of CGD among the investigated populations varies from 1:100,000 to 1: 160,000 individuals, among which 65-70% cases are caused by X-linked mutations, whereas 25% are by mutations in NCF1. The remaining cases get divided between NCF2 and CYBA genes. There are very few cases reported with p40 phox deficiency [2] . However, these percentages may change significantly depending on the ethnic background and degree of consanguinity in the population studied [3] .
The patients with CGD usually present recurrent bacterial and fungal infections in early childhood. The most common initial clinical manifestations are pneumonia, otitis, adenitis, skin infections, diarrhoea, spleen and/or liver abscesses, gingival abscesses and suppurative lymphadenitis [4] . The most common organisms associated with CGD include Staphylococcus aureus, Serratia marcescens, Salmonella species, Klebsiella species, Pseudomonas cepacia, Nocardia, Aspergillus and Candida species [5] . Additionally, the patients may have inflammatory and presumably noninfectious conditions such as granulomatous colitis or obstructive granulomas.
The laboratory diagnosis of CGD can be performed using NBT test. It is performed by stimulating the neutrophils with stimulants such as phorbol myristate acetate (PMA) which induces an oxidative response. In healthy controls, the percent positivity ranges from 90% to 100%, whereas in CGD patients, it is from 0% to 10%. The diagnosis is then confirmed by a sensitive flow cytometric assay which quantifies the oxidation of dihydrorhodamine (DHR) by neutrophils after stimulation with PMA. Identification of subtypes of CGD is not possible with these tests, however; only X-linked status can be determined in these assays if the mother is a carrier. The carrier pattern (mosaicism) in NBT and DHR tests in mother is observed due to heterogeneous population of neutrophils having abnormal and normal phagocytic function. This may suggest the possibility of XL-CGD. However, it has been documented that 10% to 20% of XL-CGD mothers do not show mosaic pattern due to the occurrence of new spontaneous mutations [6] . Genetic analysis in these patients is critical not only for the management of the patients but also for the genetic counselling and prenatal diagnosis (PND).
A recent study in our country suggests AR-CGD genotype is more common than XL-CGD [5] . AR-CGD patients are more often reported than XL-CGD patients in countries that have higher rates of consanguineous marriage. Molecular characterization of AR-CGD often becomes complex and time-consuming due to involvement of four different genes. The underlying genetic defect cannot be identified by NBT and DHR test alone, but requires molecular confirmation. Currently, more than 700 mutations have been associated with the CGD genes. The repertoire of mutations includes missense, nonsense, deletions (including large deletions of multiple exons), insertions, splice site and promoter region mutations. Novel mutations are continually being identified [7] . Thus, the genetic analysis of CGD is complex, and being a rare disease, very few centres offer the services and have a very long turnaround time.
In view of these practical difficulties, there is unmet need to explore comparatively easy and effective diagnostic tools for PND of CGD in India. The main purpose of PND was to inform and allow parents to take necessary decision based on the diagnosis of the fetus.
Here, we have explored the use of the sensitive DHR assay along with NBT to provide PND of CGD in families where molecular characterization of the index case was unavailable and parents had approached at late gestational age in pregnancy.
Materials and methods
Fetal cord blood sample collection: Informed consent was obtained from all the six couples undergoing PND in the study. The procedures followed were in accordance with the regulations of the responsible Institutional Ethics Committee and the Declaration of Helsinki. Fetal cord blood (FB) samples (1-2 mL, <0.5% of expected weight in all cases) were obtained by ultrasound-guided cordocentesis at 18 weeks of gestation. All the samples were collected in two separate EDTA vacutainers. The second vacutainer was used for prenatal testing as that had least chance of maternal contamination and was analysed within three hours of sampling. The FB sample was tested for complete hemogram. The sample with high MCV value (>110 fl) with narrow and single red cell distribution curve was accepted for analysis.
PND was offered for six families on cordocentesis sample as molecular diagnosis was not available in the index case. Phenotypic diagnosis was performed by measuring oxidative burst activity using NBT and DHR assays. The results were evaluated using previously established reference ranges [8] Mother's carrier status was checked to rule out XL-CGD in case of male patient. The Rh typing was performed in mother before the procedure. Maternal contamination was ruled out using KleihauerBetke (KB) staining and analysis of variable number of tandem repeats (VNTR) using the apolipoprotein B (ApoB), actb2, D1S80 and IgJH genes.
1. NBT test: NBT (nitro blue tetrazolium) is an electron acceptor used to detect the production of superoxide by stimulated neutrophils. NBT is soluble, yellow dye which is converted to the blue-black formazan particles as an insoluble substance by the neutrophils stimulated with PMA. Slides with PMA-treated cells were examined under microscope for calculating the percentage of cells with black formazan deposits indicating that cells are burst after stimulation. Of the six samples, NBT could not be performed in three samples due to limited volume of the sample.
2. DHR test: Flow cytometric evaluation of expression of DHR was performed using DHR and PMA protocol as mentioned in Kulkarni et al. [9] CD45 (PerCP-CY5.5, clone: HI30) and CD15 (APC, clone: HI98, BD) were used as gating marker for neutrophils. Whole blood stain-lysewash protocol was used for sample processing, and BD FACS lyse solution was used for RBC lysis. Minimum 3,000 gated neutrophils were acquired and analysed.
Results
The DHR activity ranged from 58% to 99% in the six PND samples suggesting an unaffected fetus. While performing the DHR test; due to low absolute neutrophil count (ANC), immature neutrophils and difficulty in lysis of RBC; gating of neutrophils was difficult using only CD45 antibody staining. Addition of CD15 became very important for accurate gating and analysis of neutrophil activity (Fig. 1) . None of the FB samples showed maternal contamination when tested by KB staining and VNTR analysis. All the cases were followed up post-delivery for confirmatory test by NBT and DHR. All these six children displayed normal growth and the absence of any serious infections at median follow-up of 12 months. The clinical presentation and investigations of index cases and the FB sample are summarized in Table 1 .
A note of caution: in case of index case with XL-CGD, phenotypic diagnosis becomes more crucial and requires technical skills for assessment of exact percentage of DHRpositive cells after stimulation. This is because, in such case, possibility of misdiagnosis increases as the mother's sample contains two populations of neutrophils confusing the diagnosis. The VNTR analysis rules out the possibility of maternal contamination, thus confirming the phenotypic diagnosis in case of XL-CGD.
Discussion
Currently, management of CGD involves the use of longterm antibiotic, antifungal prophylaxis and INF-gamma therapy. The management facilities have reduced the mortality rate, but morbidity still remains high due because of the breakthrough infections. Haematopoietic stem cell transplantation (HSCT) is also considered as a treatment option for stable remission of CGD. Equivalent outcomes are obtained with stem cells from matched related donors and matched unrelated donors. However, transplantations with other than perfectly matched donors are presently discouraged because of its poor success rate due to post-BMT complications [10] . Moreover, difficulties in getting a suitable donor and cost of transplantation procedure are also limiting factors in severe cases. Therefore, in families with history of CGD, genetic counselling with the possibility of carrier detection and PND becomes an important part of disease management.
Mutation detection in the index case and analysis of chorionic villus sampling performed at 10-12 weeks of gestation still remain the preferred procedure for PND in families with known molecular defects. Molecular diagnosis is essential for PND; however, timely diagnosis of molecular analysis is often not available in index case, because of the difficulties which includes complexity of the disease and lack of adequate facilities required for the setup. In case, if a family with previous history of affected child presents late in pregnancy and the pathogenic mutation in the index case was not identified at the time of PND, then in such conditions, time is crucial for the diagnosis and one needs to perform phenotypic PND.
Phenotypic PND is performed at 18 weeks, which is late compared to the other techniques of PND. However, the results are usually available within 24 hours after the procedure, which still gives enough time for safe termination of pregnancy (up to 20 weeks of gestation). It has been documented that around 37.6% of families in India go for PND in the second trimester [11] . Although, the risk to the fetus is documented to be higher with cordocentesis compared to other procedures, it is very safe when performed by an expert [11] . Phenotypic PND of CGD performed on FB obtained by cordocentesis offers considerable relief to the affected families when molecular testing is not available.
The diagnosis of CGD can be easily performed by NBT test and DHR assay on neutrophils [12] . NBT is often performed to give an additional visual confirmation of the test. The neutrophil count in the fetal blood at 18 weeks of gestation is often less compared to the cord blood or adult peripheral blood. As enough neutrophils are not seen on the slide, scoring enough neutrophils for NBT test becomes challenging in FB sample. Thus, NBT alone should not be performed, and it has to be coupled with DHR because it is more sensitive and rapid where you can quantitate more cells. It is essential to perform NBT and DHR in all the samples, but whenever the sample is limited, DHR is preferred. And that is why we could give the diagnosis in three patients only on the basis of DHR test, as we could not perform NBT for them due to inadequate sample availability at the time of diagnosis.
The flow cytometric analysis of FB sample by DHR evaluation is complicated because of the high number of nucleated RBCs, having high fetal haemoglobin content leading to difficulty in RBC lysis. Thus, accurate live gating of leucocytes by staining with CD45 antibody becomes essential [8, 11] . The commercially available DHR diagnostic kits suggest addition of CD45 antibody to study the activity in well-characterized cells. We have observed that addition of CD15 to the panel provides a better separation of neutrophils compared to CD45 gating alone (Fig. 1) . As the neutrophil proportion in FB is less, PND of CGD can be established by analysing minimum 3,000 events of neutrophils gated on higher side scatter and CD15.
Our results show that in the developing countries with modest facilities for molecular testing, NBT test and flow cytometric DHR analysis of FB samples at 18-20 weeks of gestation may offer a rapid and sensitive method for PND of CGD. We showed that whether the fetus is affected or unaffected with CGD, can be determined by phenotypic 
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